Filing summary: Global Medical REIT Inc. (NYSE: GMRE)
Entity note: The request identifies Chiron Real Estate Inc., but the supplied Form 10-Q is for Global Medical REIT Inc. This summary reflects the filing provided. It covers the quarter and six months ended June 30, 2023; statements are unaudited.
Business context
Global Medical REIT is an internally managed REIT that owns healthcare facilities and leases them to physician groups and healthcare systems, primarily under medium- to long-term leases. At quarter-end, its portfolio comprised 186 buildings and approximately 4.8 million leasable square feet. It reported 268 tenants, with no tenant representing more than 10% of rental revenue during the first half of 2023.
Key financial results
Amounts below are in millions of dollars, except per-share data. “Q2” is the three months ended June 30; “6M” is the six months ended June 30.
| Metric | Q2 2023 | Q2 2022 | 6M 2023 | 6M 2022 |
|---|---|---|---|---|
| Total revenue | $36.4 | $33.7 | $72.6 | $65.6 |
| Interest expense | $8.5 | $5.4 | $16.7 | $10.2 |
| Income before property-sale gains | $1.4 | $3.8 | $3.1 | $8.1 |
| Gain on property sales | $12.8 | — | $13.3 | — |
| Net income | $14.2 | $3.8 | $16.4 | $8.1 |
| Net income attributable to common stockholders | $11.8 | $2.2 | $12.5 | $4.9 |
| Common-stockholder EPS, basic and diluted | $0.18 | $0.03 | $0.19 | $0.07 |
| FFO per share and unit | $0.21 | $0.24 | $0.43 | $0.47 |
| AFFO per share and unit | $0.23 | $0.25 | $0.45 | $0.49 |
| Common dividend per share | $0.21 | $0.21 | $0.42 | $0.42 |
First-half operating cash flow was $33.6 million, down from $39.9 million. Investing activities provided $65.1 million, mainly reflecting property-sale proceeds; financing activities used $103.4 million, including net Credit Facility repayments and dividends. Cash and restricted cash totaled $9.8 million at June 30, versus $14.5 million at December 31, 2022; unrestricted cash was $2.5 million.
At June 30, total debt, net of issuance costs, was $625.1 million, down from $694.1 million at year-end. Total liabilities were $679.4 million and total equity was $641.4 million. The weighted-average debt rate was 4.09% at June 30. The company reported $76.1 million of unhedged variable-rate revolver borrowings; a 100-basis-point SOFR increase was estimated to raise annual interest expense by about $0.8 million. As of August 2, it had $321.0 million of unused Revolver capacity.
Material changes and unusual items
- Revenue rose 7.9% in Q2 and 10.7% in the first half, primarily due to properties acquired after June 2022 and the fuller-period contribution of earlier acquisitions.
- Interest expense increased 57% in Q2 and 64% in the first half, reflecting higher average borrowings and rates. The weighted-average debt rate for the first half was 4.32%, versus 2.92% in 2022.
- Income before property-sale gains fell to $1.4 million in Q2 and $3.1 million for the first half. Reported net income benefited materially from the $12.8 million gain on the June sale of four Oklahoma City buildings and the $0.5 million gain on a March Jacksonville sale.
- FFO and AFFO per share and unit declined year over year in both periods, despite higher revenue. These are non-GAAP measures; the filing cautions that definitions may differ among companies.
- The company acquired one facility in Redding, California, for a contractual purchase price of $6.7 million, primarily funded through OP Units. It sold five buildings in two transactions for gross proceeds of $70.4 million. Net proceeds from the Oklahoma City sale were used to repay Credit Facility borrowings.
- A new headquarters lease commenced in May 2023, creating a recorded right-of-use asset and liability of $4.6 million and approximately $7 million of total lease payments over its term.
Outlook, liquidity, and risks
The filing provides no formal earnings or FFO guidance. Management expects to meet liquidity needs through operating cash flow, debt and equity financing, OP Unit issuance, and selected property sales or recapitalizations. It reported compliance with Credit Facility covenants at June 30. Scheduled capital-improvement obligations were approximately $29.6 million, including an estimated $10.4 million expected over the next 12 months, although timing is subject to contingencies.
Interest-rate exposure remains important despite swaps hedging the $350 million Term Loan A and $150 million Term Loan B. Management noted that higher rates and inflation raise financing and operating costs, while longer-term leases may limit the speed of rent increases. Other cited risks include tenant defaults or lease non-renewals, rent collection, healthcare labor costs and reimbursement changes, acquisition competition, access to capital, and potential effects of COVID-19. The company reported no material litigation or known material environmental liability, and no material change to previously disclosed risk factors.
Most important facts for investors to verify
- Confirm the issuer identity: the provided filing is Global Medical REIT Inc., not Chiron Real Estate Inc.
- Review whether recurring operating performance supports the dividend: first-half AFFO per share and unit of $0.45 was close to the $0.42 common dividend, while FFO and AFFO declined year over year.
- Assess sensitivity to rates as hedges roll forward, especially the $76.1 million unhedged revolver balance and the August 2023/August 2024 Term Loan A swap transitions.
- Check future liquidity and refinancing needs against low unrestricted cash, debt maturities, available revolver capacity, and the preferred stock’s $77.6 million liquidation preference.
- Track tenant rent collections, capital-improvement commitments, and the release of the $1.0 million Oklahoma City sale escrow, which management expected in December 2023 absent successful buyer claims.